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Objectives: Sepsis remains a disease with a high mortality in neonates. Microcirculatory 
impairment plays a pivotal role in the development of multiorgan failure in septic newborns. 
The hemodynamic effects of recombinant activated protein C (rhAPC) were tested in an animal 
model of neonatal septic shock focusing on intestinal microcirculation.
Materials and methods: Endotoxic shock was triggered by intravenous application of 
Escherichia coli lipopolysaccarides in newborn piglets. Thereafter, five animals received a 
continuous infusion of 24 µg/kg/h rhAPC, and five received vehicle for control. Over the course 
of three hours, intestinal microcirculation was assessed by intravital microscopy every 30 min. 
Macrocirculation and blood counts were monitored simultaneously.
Results: After a short hypotensive period in all animals, the arterial blood pressure returned 
to baseline in the rhAPC-treated piglets, whereas the hypotension became increasingly severe 
in the controls. By 90 min, mean blood pressure in the controls was significantly lower than in 
the treatment group. Similar observations were made regaring microcirculation. After an early 
impairment in all study animals, functional capillary density and intestinal microcirculatory 
red blood cell velocity and red blood cell flow recovered in the rhAPC group, but deteriorated 
further in the control piglets.
Conclusion: Recombinant activated protein C protects macro- and microcirculation from 
endotoxic shock.
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Introduction
Sepsis is one of the leading causes of death in hospitalized neonates and preterm 
infants.1 Sepsis results from a systemic response to infection, which can be triggered by 
components of the microbial cell wall or microbial DNA among others. These nonself 
patterns are detected by pattern-recognition receptors (PRRs) such as Toll-like receptors 
(TLRs). Upon ligand binding, TLRs induce pro-inflammatory cytokines (eg, tumor 
necrosis factor-α [TNFα], interleukin-1 [IL-1], IL-6, IL-8), which in turn activate 
coagulation and suppress fibrinolysis by stimulating the surface expression of tissue 
factor on monocytes and endothelium. Subsequently, thrombin is generated which 
leads to deposition of fibrin, disruption of the endothelial coagulatory equilibrium, and 
ultimately in microvascular thrombosis.2 On the basis of the molecular mechanisms 
involved in sepsis, it seems likely that therapeutic interventions and drugs targeting 
the interface of coagulation and inflammation may improve microcirculation and 
microvascular blood flow.Vascular Health and Risk Management 2009:5 776
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The protein C pathway is one of the major mechanisms 
reining hemostasis. The zymogen protein C is activated by 
the thrombin–thrombomodulin complex in combination 
with the endothelial protein C receptor (EPCR). Activated 
protein C (APC) exerts its anticoagulatory effect by 
proteolytically degrading factors Va and VIIIa, and via 
facilitation of fibrinolysis through inhibition of tissue plas-
minogen activator inhibitor (PAI). APC also has an important 
anti-inflammatory role as illustrated by its amelioration of 
the inflammatory activation that occurs upon intravenous 
infusion of Escherichia coli;3 APC exerts this effect by 
inhibiting the liberation of TNFα and other pro-inflammatory 
cytokines through blocking nuclear factor-kB (NF-kB) and 
p38 mitogen-activated protein kinase activation.4–7
Protein C is commercially available as recombinant 
human APC (rhAPC; Xigris®, Eli Lilly, Indianapolis, IN, 
USA) or as the nonactivated zymogen human protein C (hPC; 
Ceprotin®, Baxter, Glendale, CA, USA). A large multicenter 
trial (PROWESS) showed a benefit for adult patients with 
severe sepsis who were treated with rhAPC.8 However, a 
multicenter trial in which rhAPC was administered to septic 
children was terminated because of an increased incidence 
in intracranial hemorrhage, especially in the subgroup of 
children younger than 60 days.9 As a result, the use of rhAPC 
in septic neonates is still limited and no multicenter trial data 
is available. Nonetheless, single-case reports describe the 
use of rhAPC in septic neonates.10–12 In addition, a beneficial 
effect of rhAPC in an animal model of neonatal ischemic 
brain injury has been reported.13 Another publication by 
our group demonstrated that the nonactivated zymogen 
protein C in neonatal septic shock was effective.14 Low 
protein C plasma levels have been identified as a predictor for 
increased mortality in the neonatal sepsis by Venkataseshan 
and colleagues.15
Studies investigating the molecular basis of inflammation 
have demonstrated increased production of pro-inflammatory 
mediators such as prostaglandins, nitric oxide, IL-1, and 
TNFα. The release of these pro-inflammatory mediators 
can result in a vasodilatory/vasoconstrictory imbalance 
and subsequent microcirculatory impairment that improves 
after the application of rhAPC in an animal model of septic 
shock.16 Since microcirculation is one of the aspects of sepsis 
that has received less attention than others, we designed a 
study which focused on the important pathophysiological 
problem of microcirculatory impairment during septic shock. 
We hypothesized that treatment with rhAPC at least partly 
reverses these deleterious effects of endotoxemia. To inves-
tigate this hypothesis, we measured several parameters of 
macro- and microcirculation in a model of neonatal endotoxic 
shock in which piglets were challenged with lipopolysac-
charide (LPS).
Methods
Intravital microscopy
The use of orthogonal polarization spectral imaging (OPS 
imaging; Cytoscan®, Cytometrics, Philadelphia, PA, USA) 
as a noninvasive method of microcirculatory assessment 
in preterm and term infants has been described by Genzel-
Boroviczeny.17 OPS imaging is a microscopic approach based 
on epi-illumination with polarized light.18 A virtual light 
source is created at a depth of about 1 mm within the tissue 
through the use of special optics. The light shining through 
the tissue is absorbed by hemoglobin, yielding an image of 
the illuminated vessel in negative contrast with a resolu-
tion of 1 pixel = 1 µm. Fluorescent dyes are not necessary. 
Capillary red blood cell velocity (RBCV) is directly measured, 
whereas functional capillary density (FCD) and capillary red 
blood cell flow (FRBC) are calculated. Functional capillary 
density (FCD [cm/cm2]) represents the fraction of capillaries 
that are perfused compared to all capillaries in a defined region 
of interest. Capillary red blood cell flow (FRBC [µm3/sec]) 
is calculated from the capillary diameter and red blood cell 
velocity (VRBC [µm/sec]) (FRBC = π/4 × D2 × RBCV).19 
Using OPS imaging, it is possible to investigate any acces-
sible surface in animals or humans such as skin, mucous 
membranes or internal organs.20 OPS has been validated for 
quantitative measurements of microcirculatory parameters in 
an animal model compared to common intravital microscopy 
with fluorescent dyes.20 In humans, OPS has been validated 
in healthy volunteers before and after venous occlusion of the 
forearm, as well as in patients with sepsis.21
Here, we captured and examined video sequences of an 
unbranched part of an arteriole and venule with a length of 
100 µm and a maximal diameter of 50 µm for RBC flow 
(FRBC) and RBC velocity (VRBC). Of the three video films 
taken at each time point, the one with the best quality was 
further used for calculation of functional capillary density 
(FCD) with an integrated calculating program (Capyscope®; 
KK Technology, Brightham, UK).
OPS microscopy has a number of intrinsic limitations. 
In order to maximize the reproducibility within our 
study and for other researchers, we applied the following 
precautions: The piglets were paralyzed to reduce the 
spontaneous movements of the intestine and therefore 
potential errors of microcirculatory measurements. Analysis 
was performed off line in order to keep intervals between Vascular Health and Risk Management 2009:5 777
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measurements identical. To avoid interindividual differences, 
one nonblinded investigator performed assessment and 
analysis of microcirculation data. Later, the video sequences 
were independently re-evaluated by four blinded investiga-
tors to prevent bias. The videos were categorized using the 
following semiquantitative scoring system:
Score 0: No capillaries visible.
  Score 1: No or few capillaries visible, low velocity or 
no visible flow.
  Score 2: Some capillaries visible, moderate velocity, 
visible flow.
  Score 3: Many capillaries visible, high velocity, flow 
obvious.
Setting
Ten German Landrace neonatal piglets (mean bodyweight 
2420 g, mean age 2 d) were used in this study. The animals 
received 0.02 mg atropine (Atropin®, Braun, Melsungen, 
Germany) and were sedated with azaperon (Stresnil®, 
Janssen-Cilag, Baar, Switzerland, 8 mg/kg i.m.). The piglets 
received a continuous infusion of glucose 10% (10 ml/kg/h) 
via a peripheral venous access during the whole study period. 
Ketamine (10 mg/kg) was given i.m., followed by insertion 
of a 3.0 CH endotracheal tube via tracheotomy. For con-
tinuous monitoring of hemodynamic parameters and blood 
sampling, a catheter (4 F; Argyle®, Sherwood Medical, 
Tullamore, Ireland) was placed into the left carotid artery. 
Median laparotomy was performed to access the ileum. 
Analgesia and sedation were achieved with 0.3 mg/kg/h 
midazolam (Dormicum®, Braun) and 1 µg/kg/h fentanyl 
(Fentanyl®, Janssen Cilag). The piglets were paralyzed 
with 0.1 mg/kg/h pancuronium (Pancuronium Curamed®, 
Curamed, Karlsruhe, Germany). Rectal body temperature 
was recorded continuously and a temperature of 38.5 °C was 
maintained with a heated mattress. Hemodynamic measure-
ments included continuous monitoring of heart rate as well as 
systolic, mean, and diastolic pressures (Monitor: Solar 8000®, 
Marquette Hellige Freiburg, Germany; Transducer: Medex 
System®, Medex, Carlsbad, CA, USA). Measurement of these 
parameters and assessment of microcirculation using OPS 
imaging (Cytoscan®) were performed simultaneously. At 
each time point, three different sites on the peritoneal surface 
of the ileum were recorded for 30 sec at 10 frames/second. 
After a stabilization period of 30 min after the surgical proce-
dure, each piglet received an intravenous bolus of 500 µg/kg 
E. coli LPS (O 111 B 04, Sigma-Aldrich Chemie GmbH, 
Munich, Germany). Five piglets received 24 µg/kg/h rhAPC 
(Xigris®, Eli Lilly) as a continuous intravenous infusion 
starting 30 min after LPS. The infusion was continued to 
the end of the study period. Five piglets received saline and 
served as controls. Hemodynamic and microcirculatory 
parameters (at three sites as described above) were assessed 
prior to endotoxemia (baseline, 0 min) and every 30 min for 
a period of three hours (30, 60, 90, 120, 150, and 180 min). 
At the same time points, blood samples were taken in which 
red blood cells (RBC), white blood cells (WBC) and platelets 
(PLT) and the hematocrit (Hct) were measured. No interven-
tion such as volume resuscitation or inotropic support was 
given. After the study period, the piglets were euthanized 
with T 61® (embrutamide/tetracaine, Hoechst, Frankfurt/
Main, Germany). Laboratory evaluation was performed by 
blinded laboratory technicians. The Committee on Animal 
Research/State of Hesse approved the protocol of this study 
(Nr F. 133/04).
Statistics
Statistic analysis was performed with Sigma Stat® (SYSTAT 
Software Inc, Richmond, CA, USA) using a two-way 
repeated measure ANOVA with Bonferroni post-hoc pair-
wise comparison on the raw data. A p  0.05 was considered 
significant. Microcirculatory parameters and mean arterial 
blood pressure (MAP) were assigned a value of 0 after sub-
jects died from hypotension. All data are displayed as mean 
values and ± SEM.
Results
Survival and bleeding complications
Two animals in the control group died of septic shock-
induced hypotension at 125 and 135 min. None of the animals 
treated with rhAPC died during the study period. None of 
the animals in either group suffered from bleeding events, 
defined as macroscopic bleeding or an obvious extravasation 
of RBC from arterioles or venules.
Hematology
Hematocrit and hemoglobin levels as well as RBC count 
did not change significantly (Table 1). There was a trend to 
reduced platelet and white blood counts after the initiation of 
endotoxic shock in all animals. The most pronounced decline 
was observed in the control group, although the difference to 
the rhAPC group was not statistically significant (Table 1).
Macrocirculation
Whereas the MAP dropped dramatically in the control piglets 
(open circles in Figure 1), the decrease in animals which 
received rhAPC was not significant. From 90 min onwards, Vascular Health and Risk Management 2009:5 778
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the difference between the treatment and the control groups 
was marked (Figure 1A) and statistically significant despite 
a considerable interindividual variability.
Microcirculation
We detected changes in the microcirculation as early as 
30 min after LPS administration. The observed impairment 
of the microcirculation increased over time in the control 
group, whereas microcirculation was preserved in the animals 
receiving rhAPC (Figure 1B to D). Although the rhAPC-
mediated protection as measured by functional capillary 
density (FDC), a parameter for perfusion, did not reach 
statistical significance due to inter-individual variability, 
the decrease in FDC in the control animals was considerable 
(Figure 1B). As shown in Figure 1C, the velocity of capil-
lary red blood cell flow (VRBC) was significantly higher in 
rhAPC-treated animals compared to the control group at 150 
and 180 min. In the late stages of the experiment, the VRBC 
was significantly reduced compared to baseline at 120 min 
and 180 min in control piglets.
Red blood cell flow (FRBC) was maintained over the 
complete study period of 180 min in the rhAPC group, 
whereas FRBC decreased in control animals. From 120 min 
onwards, FRBC was significantly higher in animals treated 
with rhAPC compared to controls.
In addition, video sequences recorded at different 
time points and under different treatment conditions were 
scored by four independent, blinded investigators. These 
volunteers were provided with one exemplary video for the 
semi-quantitative scores 0 to 3 with 0 being no flow with 
rarified capillaries and 3 standing for unimpaired flow with 
normal capillary density. Thereafter, 18 video sequences were 
assessed by each volunteer. The blinded assessors confirmed 
the results documented by the nonblinded investigator. Figure 
2 shows the LPS-induced deterioration of microcirculation 
over the course of the study period as well as the reversal 
of this effect by rhAPC as per the blinded volunteers. One 
representative video for each condition (Normal microcircu-
lation before LPS injection [t0], impaired microcirculation 
[LPS alone], and improvement by treatment with rhAPC 
[LPS + rhAPC]) can be viewed online (see http://dovepress.
com/submission_video_5863.php).
Discussion
In newborn piglets, we demonstrate impairment of the intestinal 
microcirculation early after induction of endotoxic shock and 
show that this can be prevented by treatment with rhAPC. 
Our data concur with another study that provided an insight 
into the visceral endothelial response to a sepsis trigger and 
underlined the importance of the intestine as a primary shock 
organ.21 Our study provides new affirmative data for the clinical 
observation that the use of protein C results in an improvement 
of sepsis-induced microcirculatory dysfunction.14,22
In accord with the findings of De Backer and colleagues, 
sepsis-induced alteration of the MAP was positively influ-
enced by rhAPC.22 The De Backer study demonstrated a rapid 
increase in MAP shortly after infusion of rhAPC in patients 
with septic shock. In addition, a recent study by Wang and 
colleagues pointed out the beneficial effects of rhAPC on arte-
rial blood pressure and microcirculation.23 Our study, which 
focused on the early phase of endotoxic shock, established 
that early intervention with rhAPC prevented a dramatic fall 
in blood pressure induced by injection of LPS. We did not 
measure the cardiac index, therefore we can only speculate that 
the preservation of the MAP may have partly been caused by 
a direct positive effect of rhAPC on cardiac output. However, 
it seems more likely that the improvement of the MAP was 
caused by an endothelial effect of rhAPC, for example by a 
reduction in vasodilatation in the treated animals compared 
to the controls or by a prevention of exaggerated endothelial 
inflammation and consequently reduced coagulability.
In fact, other groups as well as our own previously reported 
that both rhAPC and the zymogen human protein C concen-
trate (hPC) inhibit the induction of pro-inflammatory cyto-
kines and thereby reduce sepsis-induced endothelial injury, 
resulting in a reduction in the incidence of microthrombosis.5 
This reduction in microvascular thrombosis may play a role 
in the overall protection conferred by rhAPC.
Table 1 Blood cell counts
Hb (g/dl) 
baseline
Hb (g/dl) 
180 min
Hct (%) 
baseline
Hct (%) 
180 min
PLT (/nl) 
baseline
PLT (/nl) 
180 min
WBC(/nl) 
baseline
WBC (/nl) 
180 min
Vehicle 6.86 ± 2.79 6.47 ± 0.3 21.4 ± 9.37 20.6 ± 2.62 766 ± 215 587 ± 230 8.08 ± 2.19 4.27 ± 1.66
rhAPC 5.98 ± 0.58 6.7 ± 0.81 17.9 ± 2.25 19.7 ± 2.17 845 ± 189 635 ± 266 7.84 ± 1.67 4.6 ± 0.97
Notes: All values shown as mean ± standard error of the mean. No statistically significant differences between controls and rhAPC were found. Baseline was set at t0, 
ie, immediately prior to LPS injection.
Abbreviations: Hb, hemoglobin; Hct, hematocrit; PLT, platelets; rhAPC, recombinant activated protein C.Vascular Health and Risk Management 2009:5 779
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Figure 1 Macro- and microcirculatory effects of recombinant activated protein C (rhAPC). Endotoxic shock was induced by injection of 500 µg/kg LPS in 10 piglets at t0 (0 
min). A continuous infusion of 24 µg/kg/h rhAPC (five animals, black circles) or vehicle (five animals, open circles) was started at 30 min.
Notes: All values shown as mean ± standard error of the mean. #, p  0.05 for controls at later time points vs controls at 0 min. §, p  0.05 for rhAPC-treated piglets vs 
controls. A) mean arterial blood pressure (MAP) in mmHg. B) functional capillary density (FCD) in cm/cm2. C) red blood cell velocity (VRBC) in µm/sec. D) red blood cell 
flow (FRBC) in µm3/sec.
The major disadvantage in the clinical use of rhAPC in 
septic patients is the risk of life-threatening hemorrhage. 
In contrast with other publications in which hemorrhage 
following treatment with rhAPC was observed, there were 
no macro- or microscopic bleeding events in our study and 
Hb and Hct levels were maintained in treatment and control 
groups. Although our study does not allow any conclusions 
regarding the risk of hemorrhage and the safety of rhAPC 
in septic neonates because of a limited number of animals 
and a short observation period, we speculate that poten-
tial differences in bleeding events may have been due to 
the different APC dosing regimen employed in our study 
(infusion of 24 µg/kg/h) versus a bolus of 2 and 5 mg/kg used 
by Iba and colleagues.16 This regimen has been described by 
Russo and colleagues24 who treated pediatric cancer patients 
with severe ongoing sepsis with 24 µg/kg/h. Although these 
patients had a low platelet count (mean 9000/nl), none of them 
experienced bleeding events during treatment. However, these 
patients were not coagulopathic and therefore do not neces-
sarily represent the common pediatric sepsis patient.
Although we found no bleeding in our study, there is 
no doubt that rhAPC induces significant bleeding when 
administered to patients, thereby limiting its use in adults 
and causing extreme reluctance to employ rhAPC in infants Vascular Health and Risk Management 2009:5 780
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and children.8,9,25 As an alternative to rhAPC, there is strong 
evidence of sufficient endogenous activation of hPC in 
children with sepsis.26 We and others have shown that hPC 
is effective in the treatment of neonates and children with 
sepsis-induced purpura fulminans without increasing the risk 
of hemorrhage.14,26–28 In porcine animal models, however, 
activation of hPC is known to be less effective. Thus, a benefit 
was doubtful and we decided not to use it in this study.
Limitations of this study include the rather small number 
of subjects as well as the fact that the animal model requires 
the use of rhAPC as opposed to the clinically preferable 
zymogen hPC. In addition, data obtained by OPS microscopy 
have to be interpreted with caution, since although 
we employed an array of precautions (see Methods), it is 
impossible to eliminate all subjective elements from an OPS 
study. Nonetheless, our data present significant evidence for 
a beneficial effect of protein C on sepsis-induced deteriora-
tion of the macro- and microcirculation in an experimental 
model of neonatal septic shock. We show that microvascular 
perfusion is protected in the treatment group as measured 
by microcirculatory blood flow and functional capillary 
density. The findings of our study may encourage researchers 
to further explore protein C in neonatal diseases in which 
intestinal microcirculation is impaired.
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